Rifaximin Tablets (Xifaxan)

Elliott, William T.
May 2010
Internal Medicine Alert;5/15/2010, Vol. 32 Issue 9, p69
The article provide information on the antibacterial agent drug for patients with hepatic encephalopathy Rifaximin (Xifaxan) tablets.


Related Articles

  • Rifaximin Tablets (Xifaxan). Elliott, William T.; Chan, James // Travel Medicine Advisor;Jul2010, Vol. 20 Issue 7, p38 

    The article presents a reprint of the article "Rifaximin Tablets (Xifaxan)," by William T. Elliott and James Chan, which appeared in the May 15, 2010 issue of "Internal Medicine Alert." It offers information on rifaximin, an antibacterial agent from Salix Pharmaceuticals Ltd. that has been...

  • Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Chatellier, D.; Jourdain, M.; Mangalaboyi, J.; Ader, F.; Chopin, C.; Derambure, P.; Fourrier, F. // Intensive Care Medicine;Feb2002, Vol. 28 Issue 2, p214 

    Objectives: To describe five new cases of life-threatening cefepime-induced neurotoxicity observed in a 2-year period. Setting: A university intensive care unit. Patients: Five patients recently treated with cefepime, admitted for seizures and coma. All suffered from acute renal failure, induced...

  • Cefepime.  // Reactions Weekly;6/14/2008, Issue 1206, p9 

    The article describes the case of a 77-year-old woman who developed encephalopathy during treatment with cefepime for septicaemia. The woman has renal impairment and Alzheimer's disease. Her neurological condition improved after cefepime was discontinued and replaced with imipenem. But due to...

  • Pharmacotherapy for Hepatic Encephalopathy. Phongsamran, Paula V.; Kim, Jiwon W.; Abbott, Jennifer Cupo; Rosenblatt, Angela // Drugs;2010, Vol. 70 Issue 9, p1131 

    Hepatic encephalopathy (HE) is a challenging clinical complication of liver dysfunction with a wide spectrum of neuropsychiatric abnormalities that range from mild disturbances in cognitive function and consciousness to coma and death. The pathogenesis of HE in cirrhosis is complex and...

  • PBAC Approves XIFAXAN® (Rifaxamin a) 550 mg Cost Effectiveness in Australia.  // World Energy News;5/24/2013, p12 

    The article reports that Australia's Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 milligrams in the prevention of the recurrence of hepatic encephalopathy (HE). It notes the treatment's effectiveness where others have failed or are contraindicated for...

  • The Budd—Chiari Syndrome. Cardenas, Andres // New England Journal of Medicine;4/29/2004, Vol. 350 Issue 18, p1906 

    A letter to the editor is presented in response to the article "The Budd-Chiari Syndrome" by K.V.N. Menon et al. which appeared in the February 5, 2004 issue.

  • Restoration of learning in hepatic encephalopathy pharmacological manipulation of cGMP levels in brain. Felipo, Vicente // BMC Pharmacology;2007 Supplement 1, Vol. 7, p1 

    An abstract of the paper "Restoration of Learning in Hepatic Encephalopathy Pharmacological Manipulation of cGMP Levels in Brain," by Vicente Felipo is presented.

  • Introduction. Manns, Michael P.; Weissenborn, Karin // Metabolic Brain Disease;Mar2010, Vol. 25 Issue 1, p1 

    The article discusses various reports published within the issue, including one on the pathophysiology of hepatic encephalopathy, and neurological complications after liver transplantation.

  • Cephaloridine encephalopathy. Taylor, Roy; Arze, Ricardo; Gokal, R.; Stoddart, J.C. // British Medical Journal (Clinical Research Edition);8/8/1981, Vol. 283 Issue 6288, p409 

    Presents the case of cephaloridine infusion resulting to the development of encephalopathy. Reference to the case of a woman with tenderness in the right iliac fossa; Detection of tubular necrosis in the kidneys; Recognition of the potential of cephaloridine in the presence of impaired renal...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics